Evidence
Sheng Li Xue Bao. 2023 Oct 25;75(5):682-690.
ABSTRACT
Metabolic associated fatty liver disease (MAFLD) is a liver disease with hepatocyte steatosis caused by metabolic disorders, which is closely related to obesity, diabetes, metabolic dysfunction, and other factors. Its pathological process changes from simple steatosis, liver inflammation to non-alcoholic steatohepatitis (NASH), and then leads to liver fibrosis, cirrhosis, and liver cancer. At present, no specific therapeutics are available for treatment of MAFLD targeting its etiology. Celastrol is the main active component of the traditional Chinese medicine Celastrus orbiculatus Thunb. In recent years, it has been found that celastrol shows important medicinal value in regulating lipid metabolism, reducing fat and weight, and protecting liver, and then ameliorates MAFLD. This article reviews the related research progress of celastrol in the prevention and treatment of MAFLD, so as to provide a reference for the comprehensive development and utilization of celastrol.
PMID:37909139
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
🌐 365 Days
VR Related Evidence Matrix
